| Literature DB >> 35618888 |
Hitomi Matsuno1, Shoko Tsuchimine2, Kazunori O'Hashi2,3, Kazuhisa Sakai4, Kotaro Hattori2, Shinsuke Hidese2,5, Shingo Nakajima2,6, Shuichi Chiba2,7, Aya Yoshimura2,8, Noriko Fukuzato2, Mayumi Kando2, Megumi Tatsumi2, Shintaro Ogawa2,9, Noritaka Ichinohe4, Hiroshi Kunugi2,5, Kazuhiro Sohya10,11.
Abstract
Several lines of evidence suggest that stress induces the neurovascular dysfunction associated with increased blood-brain barrier (BBB) permeability, which could be an important pathology linking stress and psychiatric disorders, including major depressive disorder (MDD). However, the detailed mechanism resulting in BBB dysfunction associated in the pathophysiology of MDD still remains unclear. Herein, we demonstrate the role of vascular endothelial growth factor (VEGF), a key mediator of vascular angiogenesis and BBB permeability, in stress-induced BBB dysfunction and depressive-like behavior development. We implemented an animal model of depression, chronic restraint stress (RS) in BALB/c mice, and found that the BBB permeability was significantly increased in chronically stressed mice. Immunohistochemical and electron microscopic observations revealed that increased BBB permeability was associated with both paracellular and transcellular barrier alterations in the brain endothelial cells. Pharmacological inhibition of VEGF receptor 2 (VEGFR2) using a specific monoclonal antibody (DC101) prevented chronic RS-induced BBB permeability and anhedonic behavior. Considered together, these results indicate that VEGF/VEGFR2 plays a crucial role in the pathogenesis of depression by increasing the BBB permeability, and suggest that VEGFR2 inhibition could be a potential therapeutic strategy for the MDD subtype associated with BBB dysfunction.Entities:
Year: 2022 PMID: 35618888 DOI: 10.1038/s41380-022-01618-3
Source DB: PubMed Journal: Mol Psychiatry ISSN: 1359-4184 Impact factor: 15.992